24 results on '"Altman, Douglas G"'
Search Results
2. Additional file 1 of A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study
- Author
-
Speich, Benjamin, Odutayo, Ayodele, Peckham, Nicholas, Ooms, Alexander, Stokes, Jamie R., Saccilotto, Ramon, Gryaznov, Dmitry, von Niederhäusern, Belinda, Copsey, Bethan, Altman, Douglas G., Briel, Matthias, and Hopewell, Sally
- Abstract
Additional file 1: Appendix 1. The 64 components that were extracted to assess adherence of the 33 SPIRIT items (as defined for the ASPIRE project (1)). Table S1. Sensitivity analysis using different approaches* to assess the adherence to SPIRIT guidelines. Table S2. Adherence to individual SPIRIT items stratified by year and sponsorship. Table S3. Absolute increase in adequate reported selected SPIRIT item components (2012 vs 2016) for components that were not commonly reported (i.e. ≤50%) in 2012. Table S4. Results from beta regression to assess what characteristics are associated with higher proportion of adequate reporting.
- Published
- 2022
- Full Text
- View/download PDF
3. Assessing the Risk of Bias in Randomized Trials
- Author
-
Page, Matthew J., Altman, Douglas G., and Egger, Matthias
- Subjects
610 Medicine & health ,360 Social problems & social services - Published
- 2022
- Full Text
- View/download PDF
4. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, Altman, Douglas G., Dimairo, Munyaradzi, Nicholl, Jon, Meurer, William J., Cates, Christopher, Sydes, Matthew, Jemiai, Yannis, Ashby, Deborah, Yap, Christina, Waldron-Lynch, Frank, Roger, James, Marsh, Joan, Collignon, Olivier, Lawrence, David J., Bunce, Catey, Parke, Tom, Gazzard, Gus, Hopewell, Sally, Dimairo, Munyaradzi [0000-0002-9311-6920], and Apollo - University of Cambridge Repository
- Subjects
Methodology - Abstract
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised. This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process. The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text. The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites.“To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altman
- Published
- 2020
- Full Text
- View/download PDF
5. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients
- Author
-
McKenzie, Hayley S., Maishman, Tom, Simmonds, Peter, Durcan, Lorraine, Eccles, Diana, Copson, Ellen, Altman, Douglas G., Jones, Louise, Evans, Gareth, Thompson, Alastair M., Pharaoh, Paul, Hanby, Andrew, Lakhani, Sunil, Eeles, Ros, Gilbert, Fiona J., Hamed, Hisham, Hodgson, Shirley, and Apollo - University of Cambridge Repository
- Subjects
692/699/67/1347 ,article ,692/4028/67/1347 ,692/308/409 - Abstract
Background: It is not clear how the pathology, presentation and outcome for patients who present with de novo metastatic breast cancer (dnMBC) compare with those who later develop distant metastases. DnMBC is uncommon in younger patients. We describe these differences within a cohort of young patients in the United Kingdom. Methods: Women aged 40 years or younger with a first invasive breast cancer were recruited to the prospective POSH national cohort study. Baseline clinicopathological data were collected, with annual follow-up. Overall survival (OS) and post-distant relapse-free survival (PDRS) were assessed using Kaplan–Meier curves. Results: In total, 862 patients were diagnosed with metastatic disease. DnMBC prevalence was 2.6% (76/2977). Of those with initially localised disease, 27.1% (786/2901) subsequently developed a distant recurrence. Median follow-up was 11.00 years (95% CI 10.79–11.59). Patients who developed metastatic disease within 12 months had worse OS than dnMBC patients (HR 2.64; 1.84–3.77). For PDRS, dnMBC was better than all groups, including those who relapsed after 5 years. Of dnMBC patients, 1.3% had a gBRCA1, and 11.8% a gBRCA2 mutation. Conclusions: Young women with dnMBC have better PDRS than those who develop relapsed metastatic breast cancer. A gBRCA2 mutation was overrepresented in dnMBC.
- Published
- 2020
6. Additional file 8 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 8: Appendix H. Example of a CONSORT flowchart for reporting a MAMS adaptive design.
- Published
- 2020
- Full Text
- View/download PDF
7. Additional file 7 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Subjects
digestive system diseases ,humanities - Abstract
Additional file 7: Appendix G. Example of a CONSORT flowchart for reporting a response-adaptive randomisation adaptive design with frequent randomisation updates.
- Published
- 2020
- Full Text
- View/download PDF
8. Additional file 6 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 6: Appendix F. Example of a CONSORT flowchart for reporting a population enrichment adaptive design (assuming enrichment was not done at an interim analysis).
- Published
- 2020
- Full Text
- View/download PDF
9. Additional file 4 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 4: Appendix D. Example of a CONSORT flowchart for reporting 2-stage adaptive design (such as inferential seamless) that use combination test methods.
- Published
- 2020
- Full Text
- View/download PDF
10. Additional file 2 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 2: Appendix B. Additional examples of Box 13.
- Published
- 2020
- Full Text
- View/download PDF
11. Additional file 1 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 1: Appendix A. Main ACE checklist available to download.
- Published
- 2020
- Full Text
- View/download PDF
12. Additional file 5 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 5: Appendix E. Example of a CONSORT flowchart for reporting a population enrichment adaptive design (assuming enrichment was done at an interim analysis).
- Published
- 2020
- Full Text
- View/download PDF
13. Additional file 3 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 3: Appendix C. Example 2 of Box 14 (Bayesian RAR).
- Published
- 2020
- Full Text
- View/download PDF
14. Additional file 9 of The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
- Author
-
Dimairo, Munyaradzi, Pallmann, Philip, Wason, James, Todd, Susan, Jaki, Thomas, Julious, Steven A., Mander, Adrian P., Weir, Christopher J., Koenig, Franz, Walton, Marc K., Nicholl, Jon P., Coates, Elizabeth, Biggs, Katie, Hamasaki, Toshimitsu, Proschan, Michael A., Scott, John A., Ando, Yuki, Hind, Daniel, and Altman, Douglas G.
- Abstract
Additional file 9: Appendix I. Box 22 - Dummy baseline table for the TAPPS trial.
- Published
- 2020
- Full Text
- View/download PDF
15. Supplemental material for Sample size for binary logistic prediction models: Beyond events per variable criteria
- Author
-
Smeden, Maarten Van, Moons, Karel GM, Groot, Joris AH De, Collins, Gary S, Altman, Douglas G, Eijkemans, Marinus JC, and Reitsma, Johannes B
- Subjects
111099 Nursing not elsewhere classified ,111708 Health and Community Services ,160807 Sociological Methodology and Research Methods ,FOS: Health sciences ,FOS: Sociology - Abstract
Supplemental Material for Sample size for binary logistic prediction models: Beyond events per variable criteria by Maarten van Smeden, Karel GM Moons, Joris AH de Groot, Gary S Collins, Douglas G Altman, Marinus JC Eijkemans and Johannes B Reitsma in Statistical Methods in Medical Research
- Published
- 2019
- Full Text
- View/download PDF
16. Postnatal growth standards for preterm infants: the Preterm Postnatal Follow-up Study of the INTERGROWTH-21st Project
- Author
-
Villar, José, Giuliani, Francesca, Bhutta, Zulfiqar A., Bertino, Enrico, Ohuma, Eric O., Ismail, Leila Cheikh, Barros, Fernando C., Altman, Douglas G., Victora, Cesar, Noble, Julia A., Gravett, Michael G., Purwar, Manorama, Pang, Ruyan, Lambert, Ann, Papageorghiou, Aris T., Ochieng, Roseline, Jaffer, Yasmin A., Kennedy, Stephen H., Katz, M., Bhan, M. K., Garza, C., Zaidi, S., Langer, A., Rothwell, P. M., Weatherall, Sir D., Bhutta, Z. A., Villar, J., Kennedy, S., Altman, D. G., Barros, F. C., Bertino, E., Burton, F., Carvalho, M., Cheikh Ismail, L., Chumlea, W. C., Gravett, M. G., Jaff er, Y. A., Lambert, A., Lumbiganon, P., Noble, J. A., Pang, R. Y., Papageorghiou, A. T., Purwar, M., Rivera, J., Victora, C., Shorten, M., Hoch, L., Knight, H. E., Ohuma, E. O., Cosgrove, C., Blakey, I., Roseman, F., Kunnawar, N., S. H., Gu, Wang, J. H., M. H., Wu, Domingues, M., Gilli, P., Juodvirsiene, L., Musee, N., Al Jabri, H., Waller, S., Muninzwa, D., Yellappan, D., Carter, A., Reade, D., Miller, R., Salomon, L. J., Leston, A., Mitidieri, A., Al Aamri, F., Paulsene, W., Sande, J., Al Zadjali, W. K. S., Batiuk, C., Bornemeier, S., Dighe, M., Gaglioti, P., Jacinta, N., Jaiswal, S., Oas, K., Oberto, M., Olearo, E., Owende, M. G., Shah, J., Sohoni, S., Todros, T., Venkataraman, M., Vinayak, S., Wang, L., Wilson, D., Q. Q., Wu, Zhang, Y., Chamberlain, P., Danelon, D., Sarris, I., Dhami, J., Ioannou, C., Knight, C. L., Napolitano, R., Wanyonyi, S., Pace, C., Mkrtychyan, V., Al Habsi, F., Alija, M., Jimenez Bustos, J. M., Kizidio, J., Puglia, F., Liu, H., Lloyd, S., Mota, D., Ochieng, R., Rossi, C., Sanchez Luna, M., Shen, Y. J., Rocco, D. A., Frederick, I. O., Albernaz, E., Batra, M., Bhat, B. A., Di Nicola, P., Giuliani, F., Rovelli, I., Mccormick, K., Paul, V., Rajan, V., Wilkinson, A., Varalda, A., Eskenazi, B., Corra, L. A., Dolk, H., Golding, J., Matijasevich, A., de Wet, T., Zhang, J. J., Bradman, A., Finkton, D., Burnham, O., Farhi, F., Fonseca, S., Sclowitz, I. K., da Silveira, M. F., Y. P., He, Pan, Y., Yuan, Y., Choudhary, A., Choudhary, S., Deshmukh, S., Dongaonkar, D., Ketkar, M., Khedikar, V., Mahorkar, C., Mulik, I., Saboo, K., Shembekar, C., Singh, A., Taori, V., Tayade, K., Somani, A., Frigerio, M., Gilli, G., Giolito, M., Occhi, L., Signorile, F., Stones, W., Kisiang'Ani, C., Jaffer, Y. A., Al Abri, J., Al Abduwani, J., Al Habsi, F. M., Al Lawatiya, H., Al Rashidiya, B., Juangco, F. R., Andersen, H. F., Abbott, S. E., Carter, A. A., Algren, H., Sorensen, T. K., and Enquobahrie, D.
- Subjects
Male ,Longitudinal study ,medicine.medical_specialty ,Pediatrics ,Breastfeeding ,Pregnancy ,medicine ,Humans ,Fetus ,Anthropometry ,Obstetrics ,business.industry ,lcsh:Public aspects of medicine ,Medicine (all) ,Infant, Newborn ,Postmenstrual Age ,Infant ,lcsh:RA1-1270 ,General Medicine ,Reference Standards ,medicine.disease ,Cohort ,Regression Analysis ,Gestation ,Female ,business ,Breast feeding ,Infant, Premature ,Follow-Up Studies - Abstract
Summary Background Charts of size at birth are used to assess the postnatal growth of preterm babies on the assumption that extrauterine growth should mimic that in the uterus. Methods The INTERGROWTH-21 st Project assessed fetal, newborn, and postnatal growth in eight geographically defined populations, in which maternal health care and nutritional needs were met. From these populations, the Fetal Growth Longitudinal Study selected low-risk women starting antenatal care before 14 weeks' gestation and monitored fetal growth by ultrasonography. All preterm births from this cohort were eligible for the Preterm Postnatal Follow-up Study, which included standardised anthropometric measurements, feeding practices based on breastfeeding, and data on morbidity, treatments, and development. To construct the preterm postnatal growth standards, we selected all live singletons born between 26 and before 37 weeks' gestation without congenital malformations, fetal growth restriction, or severe postnatal morbidity. We did analyses with second-degree fractional polynomial regression models in a multilevel framework accounting for repeated measures. Fetal and neonatal data were pooled from study sites and stratified by postmenstrual age. For neonates, boys and girls were assessed separately. Findings From 4607 women enrolled in the study, there were 224 preterm singleton births, of which 201 (90%) were enrolled in the Preterm Postnatal Follow-up Study. Variance component analysis showed that only 0·2% and 4·0% of the total variability in postnatal length and head circumference, respectively, could be attributed to between-site differences, justifying pooling the data from all study sites. Preterm growth patterns differed from those for babies in the INTERGROWTH-21 st Newborn Size Standards. They overlapped with the WHO Child Growth Standards for term babies by 64 weeks' postmenstrual age. Interpretation Our data have yielded standards for postnatal growth in preterm infants. These standards should be used for the assessment of preterm infants until 64 weeks' postmenstrual age, after which the WHO Child Growth Standards are appropriate. Size-at-birth charts should not be used to measure postnatal growth of preterm infants. Funding Bill & Melinda Gates Foundation.
- Published
- 2015
- Full Text
- View/download PDF
17. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
- Author
-
Copson, Ellen R, Maishman, Tom C, Tapper, Will J, Cutress, Ramsey I, Greville-Heygate, Stephanie, Altman, Douglas G, Eccles, Bryony, Gerty, Sue, Durcan, Lorraine T, Jones, Louise, Evans, D Gareth, Thompson, Alastair M, Pharoah, Paul, Easton, Douglas F, Dunning, Alison M, Hanby, Andrew, Lakhani, Sunil, Eeles, Ros, Gilbert, Fiona J, Hamed, Hisham, Hodgson, Shirley, Simmonds, Peter, Stanton, Louise, Eccles, Diana M, Pharoah, Paul [0000-0001-8494-732X], Easton, Douglas [0000-0003-2444-3247], Dunning, Alison [0000-0001-6651-7166], Gilbert, Fiona [0000-0002-0124-9962], and Apollo - University of Cambridge Repository
- Subjects
Adult ,Genes, BRCA2 ,Genes, BRCA1 ,Breast Neoplasms ,Triple Negative Breast Neoplasms ,Article ,Disease-Free Survival ,Cohort Studies ,Young Adult ,Humans ,Genetic Predisposition to Disease ,Prospective Studies ,skin and connective tissue diseases ,Germ-Line Mutation ,Proportional Hazards Models ,BRCA2 Protein ,BRCA1 Protein ,Age Factors ,Prognosis ,Combined Modality Therapy ,Survival Analysis ,United Kingdom ,Patient Outcome Assessment ,Mutation ,Multivariate Analysis ,Female - Abstract
Background: Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect of a germline BRCA1 or BRCA2 mutation on breast cancer outcomes in patients with young-onset breast cancer.\ud \ud \ud \ud Methods: We did a prospective cohort study of female patients recruited from 127 hospitals in the UK aged 40 years or younger at first diagnosis (by histological confirmation) of invasive breast cancer. Patients with a previous invasive malignancy (except non-melanomatous skin cancer) were excluded. Patients were identified within 12 months of initial diagnosis. BRCA1 and BRCA2 mutations were identified using blood DNA collected at recruitment. Clinicopathological data, and data regarding treatment and long-term outcomes, including date and site of disease recurrence, were collected from routine medical records at 6 months, 12 months, and then annually until death or loss to follow-up. The primary outcome was overall survival for all BRCA1 or BRCA2 mutation carriers (BRCA-positive) versus all non-carriers (BRCA-negative) at 2 years, 5 years, and 10 years after diagnosis. A prespecified subgroup analysis of overall survival was done in patients with triple-negative breast cancer. Recruitment was completed in 2008, and long-term follow-up is continuing.\ud \ud \ud \ud Findings: Between Jan 24, 2000, and Jan 24, 2008, we recruited 2733 women. Genotyping detected a pathogenic BRCA mutation in 338 (12%) patients (201 with BRCA1, 137 with BRCA2). After a median follow-up of 8·2 years (IQR 6·0–9·9), 651 (96%) of 678 deaths were due to breast cancer. There was no significant difference in overall survival between BRCA-positive and BRCA-negative patients in multivariable analyses at any timepoint (at 2 years: 97·0% [95% CI 94·5–98·4] vs 96·6% [95·8–97·3]; at 5 years: 83·8% [79·3–87·5] vs 85·0% [83·5–86·4]; at 10 years: 73·4% [67·4–78·5] vs 70·1% [67·7–72·3]; hazard ratio [HR] 0·96 [95% CI 0·76–1·22]; p=0·76). Of 558 patients with triple-negative breast cancer, BRCA mutation carriers had better overall survival than non-carriers at 2 years (95% [95% CI 89–97] vs 91% [88–94]; HR 0·59 [95% CI 0·35–0·99]; p=0·047) but not 5 years (81% [73–87] vs 74% [70–78]; HR 1·13 [0·70–1·84]; p=0·62) or 10 years (72% [62–80] vs 69% [63–74]; HR 2·12 [0·82–5·49]; p= 0·12).\ud \ud \ud \ud Interpretation: Patients with young-onset breast cancer who carry a BRCA mutation have similar survival as non-carriers. However, BRCA mutation carriers with triple-negative breast cancer might have a survival advantage during the first few years after diagnosis compared with non-carriers. Decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences.\ud \ud \ud \ud Funding: Cancer Research UK, the UK National Cancer Research Network, the Wessex Cancer Trust, Breast Cancer Now, and the PPP Healthcare Medical Trust Grant.
- Published
- 2018
18. The satisfactory growth and development at 2 years of age of the INTERGROWTH-21st Fetal Growth Standards cohort support its appropriateness for constructing international standards
- Author
-
Villar, José, Cheikh Ismail, Leila, Staines Urias, Eleonora, Giuliani, Francesca, Ohuma, Eric O, Victora, Cesar G, Papageorghiou, Aris T, Altman, Douglas G, Garza, Cutberto, Barros, Fernando C, Puglia, Fabien, Ochieng, Roseline, Jaffer, Yasmin A, Noble, Julia A, Bertino, Enrico, Purwar, Manorama, Pang, Ruyan, Lambert, Ann, Chumlea, Cameron, Stein, Alan, Fernandes, Michelle, Bhutta, Zulfiqar A, Kennedy, Stephen H, and International Fetal and Newborn Growth Consortium for the 21(st) Century (INTERGROWTH-21(st))
- Subjects
Male ,China ,Oman ,Cephalometry ,International Fetal and Newborn Growth Consortium for the 21(st) Century (INTERGROWTH-21(st)) ,Health Status ,postnatal growth ,Nutritional Status ,India ,Reproductive health and childbirth ,World Health Organization ,Low Birth Weight and Health of the Newborn ,Fetal Development ,Paediatrics and Reproductive Medicine ,Child Development ,Pregnancy ,Clinical Research ,Preterm ,Infant Mortality ,Humans ,Longitudinal Studies ,Conditions Affecting the Embryonic and Fetal Periods ,Growth Charts ,Aetiology ,Obstetrics & Reproductive Medicine ,development ,Nutrition ,Pediatric ,INTERGROWTH-21(st) fetal growth standards ,Prevention ,Infant ,Perinatal Period - Conditions Originating in Perinatal Period ,Newborn ,Kenya ,United States ,United Kingdom ,Good Health and Well Being ,Italy ,Motor Skills ,Female ,Brazil ,2.4 Surveillance and distribution - Abstract
BackgroundThe World Health Organization recommends that human growth should be monitored with the use of international standards. However, in obstetric practice, we continue to monitor fetal growth using numerous local charts or equations that are based on different populations for each body structure. Consistent with World Health Organization recommendations, the INTERGROWTH-21st Project has produced the first set of international standards to date pregnancies; to monitor fetal growth, estimated fetal weight, Doppler measures, and brain structures; to measure uterine growth, maternal nutrition, newborn infant size, and body composition; and to assess the postnatal growth of preterm babies. All these standards are based on the same healthy pregnancy cohort. Recognizing the importance of demonstrating that, postnatally, this cohortstill adhered to the World Health Organization prescriptive approach, we followed their growth and development to the key milestone of 2 years ofage.ObjectiveThe purpose of this study was to determine whether the babies in the INTERGROWTH-21st Project maintained optimal growth and development in childhood.Study designIn the Infant Follow-up Study of the INTERGROWTH-21st Project, we evaluated postnatal growth, nutrition, morbidity, and motor development up to 2 years of age in the children who contributed data to the construction of the international fetal growth, newborn infant size and body composition at birth, and preterm postnatal growth standards. Clinical care, feeding practices, anthropometric measures, and assessment of morbidity were standardized across study sites and documented at 1 and 2 years of age. Weight, length, and head circumference age- and sex-specific z-scores and percentiles and motor development milestones were estimated with the use of the World Health Organization Child Growth Standards and World Health Organization milestone distributions, respectively. For the preterm infants, corrected age was used. Variance components analysis was used to estimate the percentage variability among individuals within a study site compared with that among study sites.ResultsThere were 3711 eligible singleton live births; 3042 children (82%) were evaluated at 2 years of age. There were no substantive differences between the included group and the lost-to-follow up group. Infant mortality rate was 3 per 1000; neonatal mortality rate was 1.6 per 1000. At the 2-year visit, the children included in the INTERGROWTH-21st Fetal Growth Standards were at the 49th percentile for length, 50th percentile for head circumference, and 58th percentile for weight of the World Health Organization Child Growth Standards. Similar results were seen for the preterm subgroup that was included in the INTERGROWTH-21st Preterm Postnatal Growth Standards. The cohort overlapped between the 3rd and 97th percentiles of the World Health Organization motor development milestones. We estimated that the variance among study sites explains only 5.5% of the total variability in the length of the children between birth and 2 years of age, although the variance among individuals within a study site explains 42.9% (ie, 8 times the amount explained by the variation among sites). An increase of 8.9 cm in adult height over mean parental height is estimated to occur in the cohort from low-middle income countries, provided that children continue to have adequate health, environmental, and nutritional conditions.ConclusionThe cohort enrolled in the INTERGROWTH-21st standards remained healthy with adequate growth and motor development up to 2 years of age, which supports its appropriateness for the construction of international fetal and preterm postnatal growth standards.
- Published
- 2018
19. Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles
- Author
-
Sekula, Peggy, Mallett, Susan, Altman, Douglas G., and Sauerbrei, Willi
- Subjects
Research Report ,Biomedical Research ,Writing ,Cancer Treatment ,lcsh:Medicine ,Guidelines as Topic ,Research and Analysis Methods ,Biochemistry ,Mathematical and Statistical Techniques ,Diagnostic Medicine ,Breast Tumors ,Breast Cancer ,Medicine and Health Sciences ,Biomarkers, Tumor ,Humans ,Statistical Methods ,lcsh:Science ,Publishing ,lcsh:R ,Biology and Life Sciences ,Cancers and Neoplasms ,Research Assessment ,Prognosis ,Oncology ,Research Design ,Physical Sciences ,Research Reporting Guidelines ,lcsh:Q ,Biomarkers ,Mathematics ,Statistics (Mathematics) ,Research Article - Abstract
Although biomarkers are perceived as highly relevant for future clinical practice, few biomarkers reach clinical utility for several reasons. Among them, poor reporting of studies is one of the major problems. To aid improvement, reporting guidelines like REMARK for tumour marker prognostic (TMP) studies were introduced several years ago. The aims of this project were to assess whether reporting quality of TMP-studies improved in comparison to a previously conducted study assessing reporting quality of TMP-studies (PRE-study) and to assess whether articles citing REMARK (citing group) are better reported, in comparison to articles not citing REMARK (not-citing group). For the POST-study, recent articles citing and not citing REMARK (53 each) were identified in selected journals through systematic literature search and evaluated in same way as in the PRE-study. Ten of the 20 items of the REMARK checklist were evaluated and used to define an overall score of reporting quality. The observed overall scores were 53.4% (range: 10%-90%) for the PRE-study, 57.7% (range: 20%-100%) for the not-citing group and 58.1% (range: 30%-100%) for the citing group of the POST-study. While there is no difference between the two groups of the POST-study, the POST-study shows a slight but not relevant improvement in reporting relative to the PRE-study. Not all the articles of the citing group, cited REMARK appropriately. Irrespective of whether REMARK was cited, the overall score was slightly higher for articles published in journals requesting adherence to REMARK than for those published in journals not requesting it: 59.9% versus 51.9%, respectively. Several years after the introduction of REMARK, many key items of TMP-studies are still very poorly reported. A combined effort is needed from authors, editors, reviewers and methodologists to improve the current situation. Good reporting is not just nice to have but is essential for any research to be useful.
- Published
- 2017
20. International standards for symphysis-fundal height based on serial measurements from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project: prospective cohort study in eight countries
- Author
-
Papageorghiou, Aris T, Ohuma, Eric O, Gravett, Michael G, Hirst, Jane, da Silveira, Mariangela F, Lambert, Ann, Carvalho, Maria, Jaffer, Yasmin A, Altman, Douglas G, Noble, Julia A, Bertino, Enrico, Purwar, Manorama, Pang, Ruyan, Cheikh Ismail, Leila, Victora, Cesar, Bhutta, Zulfiqar A, Kennedy, Stephen H, Villar, José, and International Fetal and Newborn Growth Consortium for the 21st Century INTERGROWTH-21st
- Subjects
Adult ,Male ,Fetal Growth Retardation ,Anthropometry ,Research ,Infant, Newborn ,Infant ,Pubic Symphysis ,Gestational Age ,Newborn ,Ultrasonography, Prenatal ,Fetal Development ,Pregnancy ,Abdomen ,Prenatal ,Humans ,Female ,Longitudinal Studies ,Prospective Studies ,Ultrasonography - Abstract
Objective To create international symphysis-fundal height standards derived from pregnancies of healthy women with good maternal and perinatal outcomes. Design Prospective longitudinal observational study. Setting Eight geographically diverse urban regions in Brazil, China, India, Italy, Kenya, Oman, United Kingdom, and United States. Participants Healthy, well nourished pregnant women enrolled into the Fetal Growth Longitudinal Study component of the INTERGROWTH-21st Project at 9-14 weeks’ gestation, and followed up until birth. Main outcome measures Symphysis-fundal height was measured every five weeks from 14 weeks’ gestation until birth using standardised methods and dedicated research staff who were blinded to the symphysis-fundal height measurements by turning the tape measure so that numbers were not visible during examination. The best fitting curve was selected using second degree fractional polynomials and further modelled in a multilevel framework to account for the longitudinal design of the study. Results Of 13 108 women screened in the first trimester, 4607 (35.1%) met the study entry criteria. Of the eligible women, 4321 (93.8%) had pregnancies without major complications and delivered live singletons without congenital malformations. The median number of symphysis-fundal height measurements was 5.0 (range 1-7); 3976 (92.0%) women had four or more measurements. Symphysis-fundal height measurements increased almost linearly with gestational age; data were used to determine fitted 3rd, 50th, and 97th centile curves, which showed excellent agreement with observed values. Conclusions This study presents international standards to measure symphysis-fundal height as a first level screening tool for fetal growth disturbances.
- Published
- 2016
21. Avoidable waste of research related to inadequate methods in clinical trials
- Author
-
Yordanov, Youri, Dechartres, Agnes, Porcher, Raphaël, Boutron, Isabelle, Altman, Douglas G, and Ravaud, Philippe
- Subjects
Clinical Trials as Topic ,Bias ,Meta-Analysis as Topic ,Research Design ,Research ,Humans ,Efficiency - Abstract
Objective To assess the waste of research related to inadequate methods in trials included in Cochrane reviews and to examine to what extent this waste could be avoided. A secondary objective was to perform a simulation study to re-estimate this avoidable waste if all trials were adequately reported. Design Methodological review and simulation study. Data sources Trials included in the meta-analysis of the primary outcome of Cochrane reviews published between April 2012 and March 2013. Data extraction and synthesis We collected the risk of bias assessment made by the review authors for each trial. For a random sample of 200 trials with at least one domain at high risk of bias, we re-assessed risk of bias and identified all related methodological problems. For each problem, possible adjustments were proposed that were then validated by an expert panel also evaluating their feasibility (easy or not) and cost. Avoidable waste was defined as trials with at least one domain at high risk of bias for which easy adjustments with no or minor cost could change all domains to low risk. In the simulation study, after extrapolating our re-assessment of risk of bias to all trials, we considered each domain rated as unclear risk of bias as missing data and used multiple imputations to determine whether they were at high or low risk. Results Of 1286 trials from 205 meta-analyses, 556 (43%) had at least one domain at high risk of bias. Among the sample of 200 of these trials, 142 were confirmed as high risk; in these, we identified 25 types of methodological problem. Adjustments were possible in 136 trials (96%). Easy adjustments with no or minor cost could be applied in 71 trials (50%), resulting in 17 trials (12%) changing to low risk for all domains. So the avoidable waste represented 12% (95% CI 7% to 18%) of trials with at least one domain at high risk. After correcting for incomplete reporting, avoidable waste due to inadequate methods was estimated at 42% (95% CI 36% to 49%). Conclusions An important burden of wasted research is related to inadequate methods. This waste could be partly avoided by simple and inexpensive adjustments.
- Published
- 2015
22. Test for trend across ordered groups revisited
- Author
-
Peter Sasieni, Stepniewska, Katarzyna A., and Altman, Douglas G.
- Published
- 1997
23. Interventions to improve reporting guidelines: a scoping review
- Author
-
Blanco, David, Kirkham, Jamie, Altman, Douglas G, Moher, David, Boutron, Isabelle, and Cobo, Erik
- Subjects
3. Good health - Abstract
Poster presentation of scoping review preliminary findings at Peer Review Congress 2017.  
24. Interventions To Improve Reporting Guidelines: A Scoping Review
- Author
-
Blanco, David, Kirkham, Jamie, Altman, Douglas G, Moher, David, Boutron, Isabelle, and Cobo, Erik
- Subjects
ComputingMilieux_LEGALASPECTSOFCOMPUTING ,3. Good health - Abstract
Poster presentation of scoping review preliminary findings at Peer Review Congress 2017.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.